Covid-19 aşısının virüsün bulaştırılmasını yavaşlattığı tespit edildi yeniduzen.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yeniduzen.com Daily Mail and Mail on Sunday newspapers.
Ryanair Loss Expected to Reach €950M Due to Travel Restrictions as Pandemic Persists
Feb 1 2021 · 12:20 UTC | Updated
Feb 1 2021 · 12:31 by Ibukun Ogundare · 3 min read
Photo: Pxfuel
Ryanair hopes that the vaccine rollout will eventually facilitate return to normalcy.
Ryanair Holdings Plc (NASDAQ: RYAAY) is expecting a net loss of up to €950 million in its 2021 fiscal year, which ends in March. Already, the company reported a net loss of €225.5 million in Q2 2020 and a further loss of €306 million in Q3 2020 which ended in December.
Ryanair Loss May Increase
On the 1st of February, Ryanair said its 2021 fiscal year would “continue to be the most challenging” in its 35-year history. The past and expected loss is due to travel restrictions issued by the governments amid the unprecedented global health crises. In 2020, governments tied airlines from operation for several months due to COVID-19. The recent increase in new COVID-19 cases has resulted in fresh lo
Der Profiteur: Wie Boris Johnson das Impfdesaster in der EU für sich ausnutzen kann mopo.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mopo.de Daily Mail and Mail on Sunday newspapers.
LONDON: Novavax, a vaccine undergoing trials for effectiveness against the novel coronavirus, has become the first immune dose to definitively confirm protection against the new variant of the deadly virus which was detected in the UK late last year.
A late-stage clinical trial involving over 15,000 people in the UK found that the vaccine produced by American firm Novavax is 89.3 per cent effective in preventing coronavirus and offered 85.6 per cent protection against the new British strain of Covid-19, which is up to 70 per cent more transmissible.
A smaller, separate trial also showed that it was about 60 per cent effective against the South African variant, despite concerns that this strain may not respond to vaccines.
Novavax vaccine found effective against new UK COVID-19 variant
Novavax vaccine found effective against new UK COVID-19 variant
Novavax has become the first immune dose to definitively confirm protection against the new variant of the deadly virus which was detected in the UK late last year.
advertisement
UPDATED: January 29, 2021 17:20 IST
A late-stage clinical trial involving over 15,000 people in the UK found that the vaccine produced by American firm Novavax is 89.3% effective in preventing coronavirus and offered 85.6% protection against the new British strain of COVID-19. (Reuters FILE)
Novavax, a vaccine undergoing trials for effectiveness against the novel coronavirus, has become the first immune dose to definitively confirm protection against the new variant of the deadly virus which was detected in the UK late last year.